Gensight Biologics Reaches Deal With ANSM For Opening Of Lumevoq Early Access Program In France

RefinitivЗаймёт меньше минуты

Gensight Biologics SA SIGHT:

GENSIGHT BIOLOGICS REACHES AGREEMENT WITH ANSM FOR OPENING OF LUMEVOQ® NAMED EARLY ACCESS PROGRAM (AAC) IN FRANCE
GENSIGHT BIOLOGICS SA - TARGETS Q3 2025 FOR FINALIZING DOSE-RANGING STUDY PROTOCOL
GENSIGHT BIOLOGICS SA - AAC PROGRAM TARGETED TO OPEN IN Q4 2025

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Чтобы прочитать эту статью, зарегистрируйтесь на TradingView — это бесплатно